构建癌症干细胞相关的预后模型,用于预测结直肠癌的免疫格局和药物敏感性
Jianfang Chen1, Shuang Wu1, Yu Peng1
1Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Frontiers in pharmacology
|June 28, 2023
概括
在结直肠癌 (CRC) 中确定了癌症干细胞 (CSC) 标记物,从而形成了七基因预后模型. 该模型预测了患者的结果和化疗反应,有助于CRC治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 癌症干细胞生物学
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
- 癌症干细胞 (CSCs) 在CRC进展,转移和治疗耐药性方面发挥着至关重要的作用.
- 了解CSC标志物对于改善CRC诊断和治疗至关重要.
研究的目的:
- 在结直肠癌 (CRC) 中识别关键癌症干细胞 (CSC) 标记基因.
- 分析这些CSC标记在CRC发育和患者预后中的作用.
- 为CRC患者的治疗结果和治疗反应开发一个预测模型.
主要方法:
- 利用来自CRC样本的单细胞和批量RNA测序数据.
- 应用Seurat R包用于CSC识别和标记基因发现.
- 进行共识聚类,免疫微环境分析,途径分析和氧化应激评估.
- 使用Lasso和stepAIC开发了一个预后模型,并使用prrophetic R包预测药物敏感性.
主要成果:
- 确定了29个与疾病特异性存活率 (DSS) 相关的CSC标记基因.
- 确定了两个CRC群 (CSC1和CSC2),其中CSC2的预后较差,氧化应激较高.
- 构建了一个七基因预后模型 (DRD4,DPP7,UCN,INHBA,SFTA2,SYNPO2,NXPH4),区分高风险和低风险患者.
- 在集群和风险组之间发现了药物敏感性差异,高氧化应激和风险得分的结合表明预后不佳.
结论:
- 已识别的CSC标记基因为CSC在CRC进展中的作用提供了洞察力.
- 七基因预后模型可以预测CRC患者的预后以及对免疫疗法和化疗的反应.
- 这个模型可以指导结直肠癌的个性化治疗策略.
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


